Australia's most trusted
source of pharma news
Posted 24 November 2021 PM
Novartis may be on the verge of separating itself from its generics arm, Sandoz, with investors reportedly considering a joint offer.
Swedish-based investment group EQT and the Struengmann family of Germany, who were early backers of BioNtech, are considering a joint move to purchase the generics division, German daily newspaper Handelsblatt reported, citing unnamed sources.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.